MDR Tuberculosis Treatment

Bibliographic Details
Title:	MDR Tuberculosis Treatment
Authors:	Juan Espinosa-Pereiro, Adrian Sánchez-Montalvá, Maria Luisa Aznar, Maria Espiau
Source:	Medicina, Vol 58, Iss 2, p 188 (2022)
Publisher Information:	MDPI AG, 2022.
Publication Year:	2022
Collection:	LCC:Medicine (General)
Subject Terms:	tuberculosis, MDR, treatment, Medicine (General), R5-920
More Details:	Multidrug-resistant (MDR) tuberculosis (TB), resistant to isoniazid and rifampicin, continues to be one of the most important threats to controlling the TB epidemic. Over the last few years, there have been promising pharmacological advances in the paradigm of MDR TB treatment: new and repurposed drugs have shown excellent bactericidal and sterilizing activity against Mycobacterium tuberculosis and several all-oral short regimens to treat MDR TB have shown promising results. The purpose of this comprehensive review is to summarize the most important drugs currently used to treat MDR TB, the recommended regimens to treat MDR TB, and we also summarize new insights into the treatment of patients with MDR TB.
Document Type:	article
File Description:	electronic resource
Language:	English
ISSN:	1648-9144 1010-660X
Relation:	https://www.mdpi.com/1648-9144/58/2/188; https://doaj.org/toc/1010-660X; https://doaj.org/toc/1648-9144
DOI:	10.3390/medicina58020188
Access URL:	https://doaj.org/article/603739868fa541e3a536f5ac45be9e85
Accession Number:	edsdoj.603739868fa541e3a536f5ac45be9e85
Database:	Directory of Open Access Journals